6/28/23, 12:05 AM CHAMPION PHOENIX Pathway Feedback Search Clinical Topics Home Studies CHAMPION PHOENIX CHAMPION PHOENIX Disease Disease Disease Coronary artery disease Non-ST-elevation myocardial inf ST-elev Trial question What is the effect of cangrelor in patients who were undergoing either urgent or elective PCI? Study design Multi-center Double blinded RCT Population Characteristics of study participants 27.6% female N = 11145 72.4% male 11145 patients (3051 female, 7891 male) Inclusion criteria: patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy Key exclusion criteria: pregnancy, age < 18 years, receipt of a P2Y12 inhibitor or abciximab at any time in the 7 days before randomization and receipt of eptifibatide or tirofiban or fibrinolytic therapy in the 12 hours before randomization Interventions N=5472 cangrelor (a bolus of 30 g/kg body weight followed by an infusion of 4 g/kg/minute) N=5470 clopidogrel (600 mg or 300 mg loading dose) Primary outcome Stent thrombosis at 48 hours 1.4 % 1.4 https://web.pathway.md/studies/recULL516VI0PPstl 1/2 6/28/23, 12:05 AM CHAMPION PHOENIX Pathway 1.0 % 0.8 0.7 % Significant decrease 0.3 % NNT = 167 0.0 % Cangrelor Clopidogrel Significant decrease in stent thrombosis at 48 hours (0.8% vs. 1.4%; OR 0.62, 95% CI 0.43 to 0.9) Secondary outcomes Significant decrease in intraprocedural stent thrombosis (0.6% vs. 1%; OR 0.65, 95% CI 0.42 to 0.99) Significant decrease in use of rescue therapy with a glycoprotein IIb/IIIa inhibitor (2.3% vs. 3.5%; OR 0.65, 95% CI 0.52 to 0.82) Safety outcomes No significant differences in GUSTO-defined severe bleeding, adverse events. Significant differences in procedural complications (3.4% vs. 4.5%), transient dyspnea (1.2% vs. 0.3%). Conclusion In patients who were undergoing either urgent or elective PCI and were receiving guideline- recommended therapy, cangrelor was superior to clopidogrel with respect to stent thrombosis at 48 hours. Reference Bhatt DL, Stone GW, Mahaffey KW et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4;368(14):1303-13. Open reference URL https://web.pathway.md/studies/recULL516VI0PPstl 2/2